CMPS
COMPASS PathwaysCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive late-stage readouts, constructive FDA interactions, and payer traction could re-rate COMPASS toward analyst upside within 12 months.
Posture
Mixed
Lead driver
Momentum
What changed
3 setup hits (3d) with net bullish as of 2026-06-03.
What can break
Binary clinical trial/readout failure
Momentum
98
Value
41
Sentiment
17
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $8.17 · Bull $16.08 · Bear $5.48
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-26 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $21.83
Why
Momentum98 · Δ7d -0.4
Value41 · Δ7d +0.1
Sentiment17 · Δ7d -11.0
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
98
34% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
+0.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
17
33% active weight
Current posture
7d trendSoftening
Δ7d
-11.0
Δ21d
-24.3
Why this grade
Composite grade C. Momentum 97.6 / Value 41.1 / Sentiment 17.4
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.8B
Beta
1.93
Shares Out
141.78M
P/E (TTM) · Derived
-5.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.82
Rev YoY
-
EPS YoY
-156.6%
Gross Margin
-
Op Margin
-
Net Debt
-$134.92M
Current Ratio
1.23
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology